Whether rasagiline (Anzilai) is included in medical insurance and the reimbursement conditions

Rasagiline (Rasagiline) is a selective MAO-B inhibitor used for single-agent or adjuvant levodopa treatment of Parkinson's disease (PD). It can delay the degradation of dopamine and improve motor symptoms. At present, rasagiline has been launched in China and has been included in my country's medical insurance system, which means that eligible patients can enjoy medical insurance reimbursement when purchasing it in hospital pharmacies, thereby reducing treatment costs. The specific reimbursement ratio and out-of-pocket expenses vary depending on regional medical insurance policies. Patients need to consult with the local hospital pharmacy or medical insurance department for confirmation.

In the domestic market, the price of rasagiline is mostly between a few hundred yuan and more than a thousand yuan. After medical insurance coverage, the actual payment amount of patients is significantly reduced. Especially for patients who need long-term maintenance medication, the financial burden is relieved to a certain extent. Inclusion in medical insurance not only improves the accessibility of drugs, but also provides guarantee for standardized clinical treatment, allowing more patients with Parkinson's disease to continue taking medications as prescribed and improve their quality of life.

There are various versions of rasagiline in overseas markets. For example, the price of the Turkish version of the original drug is about RMB 1,000, while the price of the Indian version of the generic drug is only more than RMB 300, which is less than half of the price of the original drug. Although the price difference is obvious, the ingredients of the drug are basically the same as those of the original drug, and the efficacy and safety are comparable to those of the original drug. This provides more flexible treatment options for patients with limited financial resources.

Overall, after rasagiline is included in medical insurance, domestic patients can obtain the drug through regular hospital channels and enjoy reimbursement policies, significantly reducing the cost of medication. When patients choose to purchase, they should choose drugs from regular channels based on their own financial situation, medical insurance policy and doctor's advice to ensure a safe, economical and reasonable long-term treatment plan. At the same time, overseas generic drugs provide additional options for some patients, but attention must be paid to legality and drug quality management.

Reference link:https://www.drugs.com